Compounded Semaglutide Is Under Fire. Here's What You Need to Know in 2025.

For a couple of years, compounded semaglutide was the worst-kept secret in American healthcare. Ozempic and Wegovy were backordered everywhere, the brand-name prices were eye-watering without insurance, and compounding pharmacies quietly stepped in to fill the gap. Millions of people got access to a medication that was otherwise completely out of reach. Now, in 2025, the FDA has changed its position, the shortage is officially "resolved," and the whole ecosystem is shifting fast. If you were using compounded semaglutide, or you're thinking about starting, you need to understand what's actually happening, not the TikTok version.

So here's the plain-English answer to the question everyone's searching: compounded semaglutide is a version of the same active ingredient found in Ozempic and Wegovy, made by licensed compounding pharmacies rather than Novo Nordisk. It isn't a generic, it isn't FDA-approved as a finished drug product, and as of early 2025, the FDA has declared the semaglutide shortage resolved, which creates significant legal pressure on pharmacies to stop making it. Whether that's good news or bad news depends entirely on your situation.

In this article, you'll get a clear breakdown of what compounded semaglutide actually is, how it compares to the branded drugs, what the FDA crackdown really means in practice, and, critically, what your options look like right now if you want medically supervised GLP-1 therapy.

What Is Semaglutide Compounding, Really?

Semaglutide is a GLP-1 receptor agonist (a drug that mimics a gut hormone called glucagon-like peptide-1). It slows gastric emptying, reduces appetite, and has significant effects on blood sugar regulation and body weight. Novo Nordisk sells it under two brand names: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Same molecule, different doses, different approvals.

Compounding is a longstanding legal practice where licensed pharmacies formulate custom medications for patients. It's how you get a pill cut into a child's dose, a cream made without a dye you're allergic to, or a medication that's been discontinued. Under US law (specifically section 503A and 503B of the Federal Food, Drug, and Cosmetic Act), pharmacies can compound copies of FDA-approved drugs when there's a documented shortage. That's the legal hook that opened the door for compounded semaglutide.

Think of it this way: if Novo Nordisk's factory is a single bakery that can't keep up with demand, compounding pharmacies are local kitchens working from the same recipe. The ingredients can be identical, but the quality control, consistency, and regulatory oversight are a different story.

Most compounded semaglutide uses semaglutide base (or sodium) rather than the exact salt form used in Ozempic and Wegovy (semaglutide as a free acid). The FDA has flagged this distinction, arguing the formulations aren't truly equivalent. Some compounders have also added ingredients like B12 or glycine, creating combination products that have no head-to-head safety data with the branded versions.

How Does Compounded Semaglutide Compare to Ozempic and Wegovy?

This is the question most people actually want answered. Here's an honest comparison:

The similarities

• Active molecule: The core peptide sequence is the same. You're getting semaglutide in both cases.
• Mechanism: GLP-1 receptor agonism works the same way regardless of manufacturer.
• Delivery: Most compounded versions are subcutaneous injections, same as Ozempic pens.
• Clinical target: Physicians prescribe compounded semaglutide for the same indications, weight management and blood sugar control.

The differences that actually matter

• FDA approval: Ozempic and Wegovy are approved finished drug products, meaning the FDA has reviewed every aspect of manufacturing, purity, potency, and stability. Compounded semaglutide has not been through this process.
• Salt form: The FDA has raised concerns that many compounders are using semaglutide sodium or acetate salt rather than the specific form used in branded drugs, which could affect bioavailability and safety.
• Dosing accuracy: Branded pens deliver a calibrated, consistent dose every time. Compounded vials require the patient to draw up the dose using a syringe. Dosing errors are a real risk if patients aren't properly educated.
• Manufacturing oversight: 503A pharmacies (retail compounders) are regulated by state boards of pharmacy. 503B outsourcing facilities face stricter federal oversight closer to pharmaceutical standards, but neither is equivalent to FDA-approved manufacturing.
• Price: Compounded versions have typically cost $200-$500 per month versus $1,300+ monthly list price for Wegovy without insurance. That gap is the entire reason this market existed.

The FDA's Position in 2025: What's Actually Changing

Here's where things get complicated. The FDA added semaglutide to its drug shortage list in 2022, which opened the legal door for compounding. In February 2025, the FDA declared the shortage resolved and gave pharmacies a grace period to wind down production. That deadline has been contested in court, with some compounding industry groups filing suit to keep the practice legal.

Here's the catch: even during the shortage, the FDA consistently maintained that compounded semaglutide wasn't risk-free. The agency received reports of adverse events, including dosing errors, hospitalizations, and product quality issues. Some of these came from patients drawing up doses incorrectly from multi-dose vials. Some came from products that didn't contain what the label claimed.

What does this mean in practice in 2025? A few things:

• Most 503A retail compounding pharmacies are under significant legal pressure to stop producing compounded semaglutide injections. Many already have.
• 503B outsourcing facilities won a temporary legal reprieve, but the situation remains in flux and changes fast. By the time you read this, the legal landscape may have shifted again.
• The FDA is also scrutinizing add-in combinations (semaglutide + B12, for example), which it considers separate new drugs requiring their own approval.
• "Semaglutide pellets" or oral compounded versions being marketed online are in an especially gray (and often red) zone. Be very careful here.

The internet wants this to be a story of Big Pharma squashing affordable access, and there's truth to that framing. But it's not the whole picture. There were real quality problems with some compounded products, and "the same molecule" doesn't automatically mean "the same drug" when manufacturing standards differ significantly.

What the Evidence Actually Shows About Semaglutide

Before we talk access, let's talk efficacy, because semaglutide's clinical track record is genuinely impressive. This isn't hype dressed up as science.

• Weight loss: In the landmark STEP 1 trial, adults with obesity taking 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That's not a rounding error.
• Cardiovascular risk reduction: The SELECT trial, published in 2023, found that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity and established cardiovascular disease, independent of weight loss alone. This was a landmark finding that expanded how clinicians think about GLP-1s.
• Blood sugar control: In the SUSTAIN trials for type 2 diabetes, semaglutide reduced HbA1c by an average of 1.5 percentage points, outperforming several competing medications.
• Emerging longevity signals: Researchers are actively investigating GLP-1 receptor agonists for effects on inflammation, neurodegeneration, and metabolic aging, though this data is still early-stage. Promising, but still unproven as a longevity intervention in the same way it's proven for weight and cardiometabolic outcomes.

The evidence base is for branded semaglutide at specific doses and formulations. Whether compounded versions produce identical clinical outcomes hasn't been studied in head-to-head trials, because running that kind of study on a compounded product isn't how the system works. That doesn't mean compounded semaglutide doesn't work. It means we don't know for certain that it performs identically.

The Reality Check: What You Should Be Skeptical About

A few things worth flagging before you make any decisions.

Not all compounding pharmacies are equal. The range is enormous. Some 503B outsourcing facilities run tight, pharmaceutical-grade operations with proper testing and documentation. Some 503A retail pharmacies are doing their best with limited oversight. And some sources you'll find via wellness clinics or online searches are closer to the Wild West end of the spectrum. The FDA's adverse event reports weren't imaginary.

Dosing errors are the main risk. This is the unsexy but important safety point. When you're drawing up a dose from a vial, getting the concentration wrong is easier than it sounds. Tenfold dosing errors have been reported. This isn't a hypothetical risk, it's a documented one. Medical supervision and proper patient education matter here in a way they don't with an auto-injector pen.

"Salt form doesn't matter" is a claim that needs evidence. Compounders often argue the salt form distinction is regulatory hair-splitting. Maybe. The FDA argues it's clinically meaningful. The honest answer is that we don't have the comparative data to definitively resolve this. That's uncertainty, not reassurance.

The shortage excuse is expiring. If the shortage is legally resolved and a pharmacy is still compounding semaglutide, the legal basis for that activity is on shaky ground. That's a risk that flows downstream to the prescriber and, indirectly, the patient.

Who Is GLP-1 Therapy Actually Right For?

GLP-1 receptor agonists like semaglutide aren't for everyone who wants to lose a few pounds. The FDA-approved indications are specific, and responsible prescribing stays close to them.

You're a reasonable candidate if:

• You have a BMI of 30 or higher (obesity), or 27 or higher with at least one weight-related condition like hypertension, type 2 diabetes, or sleep apnea
• You have type 2 diabetes or prediabetes with elevated cardiovascular risk
• You've tried lifestyle modifications seriously and they haven't been sufficient on their own
• You don't have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication)
• You're willing to engage with a clinical protocol, including labs and follow-up, not just pick up a vial and inject yourself

GLP-1 therapy works best as part of a broader metabolic health approach. It's a powerful tool, not a standalone fix. People who get the most out of it are usually also working on protein intake, muscle preservation, and lifestyle factors simultaneously.

Risks and Side Effects You Should Know About

Semaglutide's side effect profile is well-characterized from clinical trials. Most are manageable, but you should go in with eyes open.

• GI effects: Nausea, vomiting, diarrhea, and constipation are the most common, especially in the early dose-escalation phase. These typically improve over weeks but can be significant at the start.
• Muscle mass loss: Weight loss from GLP-1s includes some lean mass loss alongside fat loss. Without adequate protein intake and resistance training, this can meaningfully affect body composition.
• Gallbladder issues: Rapid weight loss of any kind increases gallstone risk. Semaglutide is no exception.
• Pancreatitis: Rare but reported. Anyone with a history of pancreatitis should discuss this carefully with their physician.
• Thyroid concerns: Animal studies showed thyroid C-cell tumors at high doses. Human relevance is uncertain, but it's why medullary thyroid cancer history is a contraindication.
• Dosing errors (compounded formulations specifically): As discussed, the syringe-based delivery of compounded vials adds a dosing variable that auto-injector pens eliminate.

Clinical supervision isn't a box-checking exercise here. It's what catches these issues before they become problems, and it's what adjusts your dose escalation schedule based on how you're actually responding.

How to Get Started: GLP-1 Therapy at Healthspan

Given everything happening with compounded semaglutide's legal status in 2025, the most defensible path to GLP-1 therapy right now runs through FDA-approved branded products, prescribed and monitored by clinicians who know what they're doing.

Healthspan's GLP-1 Longevity Care protocol is built around exactly this. Rather than handing you a vial and a syringe and wishing you luck, the protocol includes an initial consultation to review your labs, health history, and metabolic goals, before a single dose is prescribed. Dosing is structured around the published titration schedules that minimize GI side effects while getting you to a therapeutic dose that actually works. Follow-up is built in, not optional, because that's where adjustments happen and where the clinical value actually lives.

For patients who qualify and are looking at branded options, Healthspan also offers Wegovy Pen with Ongoing Care and Wegovy Pill with Ongoing Care, as well as access to tirzepatide (the dual GIP/GLP-1 agonist with an even stronger efficacy profile) through Zepbound with Ongoing Care and Zepbound KwikPen with Ongoing Care. If you're newer to this space, tirzepatide has shown weight loss outcomes that outperform semaglutide in head-to-head trials, so it's worth a conversation with your clinician about which makes more sense for your profile.

For patients interested in complementing GLP-1 therapy with broader metabolic optimization, the SGLT2 Protocol and Acarbose are worth exploring alongside your physician, as they address glucose metabolism through complementary mechanisms.

The bottom line: if GLP-1 therapy is right for you, doing it through a supervised clinical protocol is how you get the most out of it and avoid the pitfalls that have made compounded versions controversial. Start with a consultation at Healthspan and let your labs and health history drive the decision.

Frequently Asked Questions About Semaglutide Compounding

Is compounded semaglutide still legal in 2025?

It depends on the type of pharmacy and the current legal status of ongoing litigation. The FDA declared the semaglutide shortage resolved in early 2025, which removed the primary legal basis for most compounding. Some 503B outsourcing facilities have been operating under a temporary legal reprieve from court rulings, but this situation is actively evolving. As of mid-2025, most 503A retail pharmacies have been required to stop. Check with your provider for the current status.

Is compounded semaglutide as effective as Ozempic or Wegovy?

The core active peptide is the same molecule, but there are no head-to-head clinical trials comparing compounded formulations to branded products. The FDA has raised concerns about differences in salt form, manufacturing quality, and consistency. Many patients have reported effective results with compounded versions, but "effective for some people" isn't the same as "proven equivalent" in a clinical trial sense.

Why is compounded semaglutide so much cheaper than Wegovy?

Branded Wegovy costs over $1,300 per month at list price because that price reflects Novo Nordisk's R&D investment, clinical trials, FDA approval process, and marketing. Compounding pharmacies bypass all of that. They're purchasing raw semaglutide API (active pharmaceutical ingredient) and formulating it, without the regulatory infrastructure that branded drugs require. That's why compounded versions have typically run $200-$500 per month.

What are the risks of using compounded semaglutide from an online clinic?

The main risks include dosing errors from vial-based delivery, variable product quality depending on the compounding pharmacy's standards, potential use of different salt forms with unclear clinical equivalence, and lack of proper medical supervision. The FDA has received reports of hospitalizations related to compounded semaglutide, primarily from dosing errors. Working with a physician who monitors labs and adjusts dosing is the most important risk-mitigation step.

What's the difference between semaglutide and tirzepatide?

Semaglutide (Ozempic, Wegovy) activates one receptor: GLP-1. Tirzepatide (Zepbound, Mounjaro) activates two: GLP-1 and GIP. In clinical trials, tirzepatide has shown greater average weight loss than semaglutide, with participants losing up to 20-22% of body weight at the highest doses. Both are effective; the right choice depends on your individual health profile, tolerability, and clinical goals.

Can I switch from compounded semaglutide to a branded GLP-1 medication?

Yes, and many people are making this transition now as compounding access tightens. The dose conversion isn't always one-to-one since compounded formulations vary, so the transition should be managed by a clinician who can determine the appropriate starting dose for the branded product and monitor your response. Don't assume your compounded dose directly maps to a branded pen setting.

Does semaglutide cause muscle loss?

Weight loss of any kind includes some loss of lean mass alongside fat. Semaglutide is no exception, and some studies have shown muscle loss comprising a meaningful fraction of overall weight lost. Mitigating this requires adequate dietary protein (typically 1.2-1.6g per kg of body weight) and resistance training. A clinically supervised protocol should address body composition, not just the number on the scale.